Back to search
Scientific Name: Clofibrate
Brand Name: Not Available
Company Owner: Wyeth ayerst laboratories, Banner pharmacaps inc, Sandoz inc, Teva pharmaceuticals usa inc, Usl pharma inc, Watson laboratories inc
Mechanism Of Action Clofibrate increases the activity of extrahepatic lipoprotein lipase (LL) , thereby increasing lipoprotein triglyceride lipolysis. Chylomicrons are degraded, VLDLs are converted to LDLs, and LDLs are converted to HDL. This is accompanied by a slight increase in secretion of lipids into the bile and ultimately the intestine. Clofibrate also inhibits the synthesis and increases the clearance of apolipoprotein B, a carrier molecule for VLDL. Also, as a fibrate, Clofibrate is an agonist of the PPAR-α receptor[4] in muscle, liver, and other tissues. This agonism ultimately leads to modification in gene expression resulting in increased beta-oxidation, decreased triglyceride secretion, increased HDL, increased lipoprotein lipase activity.
Description of the Drug: Clofibrate is a fibric acid derivative used to treat hypertriglyceridemia and high cholesterol.
Protein Data Bank: Not Available
Source: DrugBank Online – Retrieved 2023-01-23 from